Article

VIDEO SPECIAL: The Cardiac Dangers of Hydroxychloroquine and Azithromycin

Dr. Mariell Jessup, Chief Science and Medical Officer at the AHA discusses the cardiac dangers of combining hydroxychloroquine and azithromycin to treat coronavirus patients with underlying heart disease, the controversy surrounding putting medical students and trainees on the frontlines of COVID-19 too soon, and the changing roles of telemedicine.

Dr. Mariell Jessup, Chief Science and Medical Officer at the AHA discusses the cardiac dangers of combining hydroxychloroquine and azithromycin to treat coronavirus patients with underlying heart disease, the controversy surrounding putting medical students and trainees on the frontlines of COVID-19 too soon, and the changing roles of telemedicine.

Related Videos
Steve Nissen, MD | Credit: Cleveland Clinic
Harpreet Bhatia, MD: Benefits of Universal Screening for Lp(a) Levels
Benjamin Scirica, MD | Credit: Brigham and Women's Hospital
Heather Johnson, MD: How to Combat Misconceptions of Statin Drugs in Your Patients
Nihar Desai, MD | Credit: HCPLive.com
Laurence Sperling, MD | Credit: Emory University
Tom C. Nguyen, MD: Evolving Roles of TAVR, SAVR in Aortic Valve Disease | Image Credit: Baptist Health
Related Content
Optimizing GDMT in Heart Failure Could Slash Global Mortality Rates | Image Credit: Twitter
October 9th 2024

Optimizing GDMT in Heart Failure Could Slash Global Mortality Rates

Connor Iapoce
Taher Modarressi, MD | Credit: X.com
October 3rd 2024

Don't Miss a Beat: Putting Evidence-Based Cardiometabolic Therapies into Practice, with Taher Modarressi, MD

Muthiah Vaduganathan, MD, MPH Stephen Greene, MD
FDA Decisions to Watch in Q4 2024 thumbnail
October 4th 2024

5 FDA Decisions to Watch in Q4 2024

Patrick Campbell
default thumbnail for Don't Miss a Beat podcast.
September 2nd 2024

Don't Miss a Beat: Finerenone's Role in Heart Failure from ESC Congress Data

Muthiah Vaduganathan, MD, MPH Stephen Greene, MD
Rahul Aggarwal, MD | Credit: LinkedIn
October 2nd 2024

If Successful, Inclisiran Primary Prevention Trial Could Expand Patient Population by More than 22 Million

Patrick Campbell
HCPLive Cardiology September 2024 Month in Review thumbnail
October 2nd 2024

Cardiology Month in Review: September 2024

Patrick Campbell
© 2024 MJH Life Sciences

All rights reserved.